2016 Full Year Results Investor Presentation

Michael Kavanagh

CEO & President

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Nanosonics (the "Company"). While Nanosonics has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company.

The information does not constitute advice of any kind and should not be relied on as

such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

2016 Nanosonics | 2

Corporate Mission

We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted,and introducing innovative technologies that deliver improved standards of care.

2016 Nanosonics | 3

Company overview

  • Healthcare company specialised in the development and commericalisation of infection control solutions

  • First product, trophon®EPR - proprietary automated technology for low temperature, high level disinfection of ultrasound probes

  • Approved for sale in most major markets including: US, Canada, ANZ, Europe, Singapore, HK, South Korea, Japan

  • 150 Staff across Australia, US, Canada UK, Germany and France

  • Sold through direct sales and distributors including leadings brands: GE Healthcare, Toshiba and Miele Professional

  • Active R&D program targeting expansion of product portfolio for Infection Prevention market

2016 Nanosonics | 4

Key Corporate Data

Share price*

$2.80

Shares on issue*

295.93 million

Market capitalisation*

$829 million

Liquidity* (30 day avg.)

598,000 shares

Cash (30 June 16)

$48.8 million

Share register breakdown

Founders/Related Parties 18%

Institutions 50%

Private 32%

* As at 17 August 2016

Nanosonics Limited published this content on 22 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 August 2016 07:19:04 UTC.

Public permalinkhttp://www.publicnow.com/view/1547638BB82D6680C35A2443790888552CA85BB1